Life Sciences
Safety Signals Are Speaking Every Language. Are You Listening?
At last month’s 5th Pharmacovigilance & Drug Safety Conference in…
What It Feels Like to Wait for a Treatment That Doesn’t Exist
One patient’s journey through rare disease diagnosis, clinical trial participation,…
Clinical Trials Are Complex. Workflows Shouldn’t Make Them Harder.
As clinical trials scale across systems, vendors, countries, and languages,…
Accessibility in Clinical Trials Isn’t Optional. It’s Foundational to Better Recruitment.
Patient recruitment has always been one of the most challenging…
MDR Reform and the Future of Multilingual Compliance for Medical Device Companies
How documentation strategy, translation risk, and regulatory transparency are evolving…
EMA’s Guiding Principles on LLMs: Reshaping Regulatory Translation
Discover how the EMA’s Guiding Principles on LLMs are transforming…
Creating a Future-Ready Model for a Global MedTech Leader
Discover how a global MedTech leader deployed OPAL Enable to…
How FDA and EMA Shape Linguistic Validation in Clinical Research
As clinical research becomes global, understanding how to meet regulatory…
EUDAMED and the New Reality for Medical Device Companies
What increased transparency means for post-market surveillance and multilingual compliance.
From Pressure to Possibility: Key Insights from our MedTech Roundtable
Anja Schaefer, Global Head of Commercial for Welo Life Sciences,…